The global inflammatory bowel diseases (IBD) drug market is estimated at $8.5bn in 2016 and $9.5bn in 2020. Biologic therapies are expected to be the main drivers of growth in the world IBD drug market over the forecast period. In 2016, the biologics submarket generated revenues of $5.8bn, accounting for 68% of the global IBD drug market.
How this report will benefit you
Read on to discover how you can exploit the future business opportunities emerging in this sector.
In this brand new 200-page report you will receive 89 tables and 50 figures – all unavailable elsewhere.
The 200-page report provides clear detailed insight into the global inflammatory bowel diseases (IBD) drug market. Discover the key drivers and challenges affecting the market.
By ordering and reading our brand new report today you stay better informed and ready to act.
Report Scope
• Global Inflammatory Bowel Diseases (IBD) Drug Market forecasts from 2017-2027
• Submarket forecasts from 2017-2027:
– Biologics
– Aminosalicylates
– Antibiotics
– Corticosteroids
– Immunomodulators
• Revenue forecast from 2017-2027 for 17 leading products:
– Humira
– Remicade
– Lialda
– Asacol
– Pentasa
– Xifaxan
– Cimzia
– Tysabri
– Simponi
– Canasa/Salofalk
– Entyvio
– Apriso
– Medrol
– Neoral
– Entocort
– Uceris
– Azulfidine
• Revenue forecasts from 2017-2027 for 11 countries:
– US
– Japan
– Germany, France, UK, Spain and Italy (EU5)
– Brazil, Russia, India and China (BRIC)
• Discussions on research and development, including drug candidates in these classes:
– Interleukin (IL) inhibitors
– Cell-adhesion molecule (CAM) inhibitors
– TNF-alpha inhibitors
– Stem cell therapies
– JAK inhibitors
– Toll-like receptor agonists
• Assessment of selected leading companies that hold major market shares in the inflammatory bowel diseases drug industry
• Discussions on trends in the industry and assesses strengths and weaknesses, as well as opportunities and threats (SWOT). It also analyses social, technological, economic and political factors influencing that industry and market (STEP)
Visiongain’s study is intended for anyone requiring commercial analyses for the Global Inflammatory Bowel Diseases (IBD) Drug Market. You find data, trends and predictions.
Buy our report today Inflammatory Bowel Diseases Market Analysis: Aminosalicylates, Antibiotics, Corticosteroids, Immunomodulators, Biologics, Crohn’s Disease, Ulcerative Colitis.
Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6
1. Report Overview
1.1 World IBD Drugs Market: Overview of Findings
1.2 Why You Should Read This Report
1.3 How the Study Delivers
1.4 Main Questions Covered in the Analysis
1.5 Who Is This Report For?
1.6 Methods of Research and Analysis
1.7 Frequently Asked Questions (FAQ)
1.8 Associated Reports
1.9 About Visiongain
2. Introduction to the Inflammatory Bowel Disease Drug Market
2.1 What is Inflammatory Bowel Disease (IBD)?
2.2 Classification of IBD
2.3 Symptoms and Diagnosis of IBD
2.4 Multifactorial Causes of IBD
2.5 How Common is IBD?
2.6 What Are the Treatment Options for IBD?
2.6.1 Aminosalicylates – The Most Common therapy
2.6.2 Antibiotics – Will There Be Any Supporting Evidence Soon?
2.6.3 Corticosteroids – Uptake from Uceris?
2.6.4 Immunomodulators – Slow to Act?
2.6.5 Monoclonal Antibodies – Not cost-effective?
2.7 Treatment Goals for IBD – Treat-to-Target Approach?
2.8 Treatment Algorithm – is Top-Down Approach the Future Direction?
3. The World Inflammatory Bowel Disease Drug Market, 2017-2027
3.1 The Inflammatory Bowel Disease Market in 2016 and 2017
3.2 Forecast 2017-2027: Impacted by Biosimilars?
3.3 Biologic Therapies Forecast 2017-2027 – Driving the Market
3.4 Aminosalicylates Forecast 2017-2027: The Work Horse of IBD Market
3.5 Antibiotics Forecast 2017-2027: Growing Despite Challenges
3.6 Corticosteroids Forecast 2017-2027: Driven by Uceris
3.7 Immunomodulators Forecast 2017-2027 – Will Slowly Lose Market Share
4. Market Prospects for Leading IBD Drugs, 2017-2027
4.1 Humira (AbbVie) – Growing in the First Half of Forecast Period
4.1.1 Humira: Forecast and Analysis, 2017-2027
4.2 Remicade (Janssen Biotech) – Will Slowly be Eroded by Biosimilars
4.2.1 Remicade: Forecast and Analysis, 2017-2027
4.3 Asacol (Allergan) – Threat from Generic Competition
4.3.1 Asacol: Forecast and Analysis, 2017-2027
4.4 Pentasa (Shire) – Differentiated by Its Delivery System
4.4.1 Pentasa: Forecast and Analysis, 2017-2027
4.5 Lialda (Shire) – Will Improved Compliance Increase Revenue?
4.5.1 Lialda: Forecast and Analysis, 2017-2027
4.6 Tysabri (Perrigo) – Still Protected by Patent
4.6.1 Tysabri: Forecast and Analysis, 2017-2027
4.7 Xifaxan (Valeant) – Still Growing Significantly
4.7.1 Xifaxan: Forecast and Analysis, 2017-2027
4.8 Cimzia (UCB) – How Will It Fare Against Biosimilars?
4.8.1 Cimzia: Forecast and Analysis, 2017-2027
4.9 Entocort (AstraZeneca) – A Slow and Steady Decline?
4.9.1 Entocort: Forecast and Analysis, 2017-2027
4.10 Neoral (Novartis) – Will its Side Effect Profile Hamper Sales Growth?
4.10.1 Neoral: Forecast and Analysis, 2017-2027
4.11 Medrol (Pfizer) – Another Leading Steroid
4.11.1 Medrol: Forecast and Analysis, 2017-2027
4.12 Canasa (Allergan) – Will a Generic Competitor Soon Be Available?
4.12.1 Canasa/Salofalk: Forecast and Analysis, 2017-2027
4.13 Apriso (Valeant) – Challenger to Asacol?
4.13.1 Apriso: Forecast and Analysis, 2017-2027
4.14 Azulfidine (Pfizer) – Tried, Tested and Staying in the Market
4.14.1 Azulfidine: Forecast and Analysis, 2017-2027
4.15 Entyvio (Takeda Pharmaceuticals) – Driving the Biologics Segment
4.15.1 Entyvio: Forecast and Analysis, 2017-2027
4.16 Simponi (Janssen Biotech) – Rising Star for the Market?
4.16.1 Simponi: Forecast and Analysis, 2017-2027
4.17 Uceris (Valeant) – Meeting Patients’ Needs with Its Delivery System
4.17.1 Uceris: Forecast and Analysis, 2017-2027
5. Leading National Markets: Sales Outlooks, 2017-2027
5.1 IBD Drugs - Leading National Markets 2016
5.2 The US IBD Drug Market, 2017-2017 – The World Leader
5.3 The Japanese IBD Drug Market, 2017-2027 – Growing Significantly?
5.4 The EU-5 IBD Drug Market, 2017-2027 – Driven by the UK
5.4.1 The German IBD Drug Market, 2017-2027
5.4.2 The French IBD Drug Market, 2017-2027
5.4.3 The UK IBD Drug Market, 2017-2027
5.4.4 The Spanish IBD Drug Market, 2017-2027
5.4.5 The Italian IBD Drug Market, 2017-2027
5.5 IBD Drug Markets in BRIC Countries – Taking More Market Share
5.5.1 The Brazilian IBD Drug Market, 2017-2027
5.5.2 The Russian IBD Drug Market, 2017-2027
5.5.3 The Indian Drug Market, 2017-2027
5.5.4 The Chinese IBD Drug Market, 2017-2027
6. The R&D Pipeline for Inflammatory Bowel Disease, 2016
6.1 Top Marketed and pipeline products – Launch dates and Patent expiry
6.2 Interleukin (IL) Inhibitors – One of the Main Areas of Innovation
6.2.1 CyCol (Sigmoid Pharma)
6.2.2 PF-04236921 (Pfizer)
6.2.3 QAX 576 (Novartis)
6.2.4 TNF Kinoid (Neovacs)
6.2.5 Vidofludimus (4SC) – Suspended
6.2.6 Stelara (Ustekinumab, CNTO 1275, Janssen Biotech)
6.3 Cell-Adhesion Molecule (CAM) Inhibitors – A Promising Avenue
6.3.1 AJG 511 (Ajinomoto Pharmaceutical Co.)
6.3.2 AJM 300 (Ajinomoto Pharmaceuticals)
6.3.3 MEDI 7183/AMG 181 (AstraZeneca)
6.3.4 Etrolizumab (Roche)
6.3.5 PF-00547659 (Pfizer)
6.3.6 Alicaforsen (ISIS 2302, Atlantic Healthcare)
6.4 TNF-α Inhibitors – a Specific Target
6.4.1 AVX-470 (Avaxia Biologics)
6.4.2 Ozoralizumab (ALX-0061, Ablynx)
6.5 Stem Cell Therapies – Basis for a Cure?
6.5.1 Ovasave (TxCell)
6.5.2 MultiStem (Athersys and Pfizer)
6.5.3 Prochymal (Remestemcel-L, Osiris Therapeutics)
6.5.4 Cx601 (TiGenix)
6.6 JAK Inhibitors – New Target Pathway
6.6.1 JNJ-54781532 (Janssen)
6.6.2 Xeljanz, (Tofacitinib, CP-690550, Pfizer)
6.7 Toll-like Receptor Agonists
6.7.1 BL-7040 (BioLineRX)
6.7.2 Kappaproct (InDex Pharmaceuticals)
6.8 Other Classes of Agent
6.8.1 Trichuris suis ova (CNDO-201, Coronado Biosciences)
6.8.2 GLPG0974 (Galapagos)
6.8.3 RPC1063 (Receptos/now Celgene)
6.8.4 SGX203 (Soligenix)
6.8.5 Mongersen (GED-0301, Celgene)
6.8.6 Tetomilast (OPC-6535, Otsuka)
6.8.7 Laquinimod (Active Biotech)
6.8.8 RHB-104 (RedHill Biopharma)
6.8.9 Ozanimod (Celgene)
6.8.10 GED-0301 (Celgene)
6.9 Biosimilar Candidates – Promising Competitors of Leading Biologics
6.9.1 Adalimumab Biosimilars
6.9.2 Infliximab Biosimilars
7. Drivers and Restraints in the Inflammatory Bowel Disease Drug Industry and Market, 2016
7.1 SWOT and STEP Analyses of the IBD Drugs Market
7.2 What Factors Will Stimulate the IBD Market?
7.2.1 Increasing Disease Incidence in Most National Markets
7.2.2 Better Diagnosis – Early Referrals
7.2.3 Delivery Systems Improve Existing Drugs
7.2.4 Biological Drugs – Driving the Market Significantly
7.2.5 Socioeconomic Costs of IBD
7.3 What Factors Will Restrain the Market?
7.3.1 Lack of Understanding of Disease Aetiology
7.3.2 Compliance – Frequent Dosing is Inconvenient
7.3.3 Limitations of Biologics – Side Effect Profiles
7.3.4 The Possible Development of Alternative Treatments
7.3.5 Surgery – Treatment for Recalcitrant IBD
7.3.6 Health Care Cost Containment
8. Leading Companies in the IBD Pharmaceuticals Market, 2016
8.1 The Largest Companies by Revenue
8.1.1 AbbVie
8.1.2 Janssen Biotech
8.1.3 Allergan
8.1.4 Shire Pharmaceuticals
9. Conclusions of the Study
9.1 The IBD Drugs Market Will Expand from 2017 to 2027
9.2 Aminosalicylates and Other Non-Biologic Treatments
9.3 Biological Treatments Dominate the Market
9.4 Improvements Needed in IBD Therapy
Associated Visiongain Reports
Visiongain Report Sales Order Form
About Visiongain
Visiongain Report Evaluation Form
List of Tables
Table 2.1 Differentiating Crohn’s Disease and Ulcerative Colitis
Table 2.2 Worldwide Prevalence Rates for IBD, 2016
Table 2.3 Worldwide Incidence Rates for IBD, 2016
Table 2.4 Geographical Variations in the Incidence of IBD, 2016
Table 2.5 Other Drug Types Used to Treat IBD, 2016
Table 2.6 Treatment Protocol for IBD, 2016
Table 3.1 Global IBD Drug Sales ($m), Annual Growth Rates (%) and Market Shares (%) by Segment, 2016 and 2017
Table 3.2 Global IBD Drug Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2016-2027
Table 3.3 Global IBD Drug Forecast by Drug Category: Revenues ($m), AGR (%), CAGR (%), 2016-2027
Table 3.4 Global IBD Drug Market Drivers and Restraints 2017-2027
Table 3.5 Global Biologics Forecast for IBD Market: Revenues ($m), AGR (%), CAGR (%), 2016-2027
Table 3.6 Global Biologic Therapies Drivers and Restraints, 2017-2027
Table 3.7 Global Aminosalicylates Forecast for IBD Market: Revenues ($m), AGR (%), CAGR (%), 2016-2027
Table 3.8 Global Aminosalicylates Drivers and Restraints, 2017-2027
Table 3.9 Global Antibiotics Forecast for IBD Market: Revenues ($m), AGR (%), CAGR (%), 2016-2027
Table 3.10 Global Antibiotics Drivers and Restraints, 2017-2027
Table 3.11 Global Corticosteroids Forecast for IBD Market: Revenues ($m), AGR (%), CAGR (%), 2016-2027
Table 3.12 Global Corticosteroids Drivers and Restraints, 2017-2027
Table 3.13 Global Immunomodulators Forecast for IBD Market: Revenues ($m), AGR (%), CAGR (%), 2016-2027
Table 3.14 Global Immunomodulators Drivers and Restraints, 2017-2027
Table 4.1 Leading IBD Treatments by Revenue ($m), 2016
Table 4.2 Leading IBD Medicines: Revenue Forecasts ($m), AGR (%), 2016-2027
Table 4.3 World Humira Revenue Forecast: Revenues ($m), AGR (%), CAGR (%), 2016-2027
Table 4.4 Drivers and Restraints for Humira, 2017-2027
Table 4.5 World Remicade Forecast: Revenues ($m), AGR (%), CAGR (%), 2016-2027
Table 4.6 Drivers and Restraints for Remicade, 2017-2027
Table 4.7 World Asacol Forecast: Revenues ($m), AGR (%), CAGR (%), 2016-2027
Table 4.8 Drivers and Restraints for Asacol, 2017-2027
Table 4.9 World Pentasa Forecast: Revenues ($m), AGR (%), CAGR (%), 2016-2027
Table 4.10 Drivers and Restraints for Pentasa, 2017-2027
Table 4.11 World Lialda Forecast: Revenues ($m), AGR (%), CAGR (%), 2016-2027
Table 4.12 Drivers and Restraints for Lialda, 2017-2027
Table 4.13 World Tysabri Forecast: Revenues ($m), AGR (%), CAGR (%), 2016-2027
Table 4.14 Drivers and Restraints for Tysabri, 2017-2027
Table 4.15 World Xifaxan Forecast: Revenues ($m), AGR (%), CAGR (%), 2016-2027
Table 4.16 Drivers and Restraints for Xifaxan, 2017-2027
Table 4.17 World Cimzia Forecast: Revenues ($m), AGR (%), CAGR (%), 2016-2027
Table 4.18 Drivers and Restraints for Cimzia, 2017-2027
Table 4.19 World Entocort Forecast: Revenues ($m), AGR (%), CAGR (%), 2016-2027
Table 4.20 Drivers and Restraints for Entocort, 2017-2027
Table 4.21 World Neoral Forecast: Revenues ($m), AGR (%), CAGR (%), 2016-2027
Table 4.22 Drivers and Restraints for Neoral, 2017-2027
Table 4.23 World Medrol Forecast: Revenues ($m), AGR (%), CAGR (%), 2016-2027
Table 4.24 Drivers and Restraints for Medrol, 2017-2027
Table 4.25 World Canasa Forecast: Revenues ($m), AGR (%), CAGR (%), 2016-2027
Table 4.26 Drivers and Restraints for Canasa, 2017-2027
Table 4.27 World Apriso Forecast: Revenues ($m), AGR (%), CAGR (%), 2016-2027
Table 4.28 Drivers and Restraints for Apriso, 2017-2027
Table 4.29 World Azulfidine Forecast: Revenues ($m), AGR (%), CAGR (%), 2016-2027
Table 4.30 Drivers and Restraints for Azulfidine, 2017-2027
Table 4.31 World Entyvio Forecast: Revenues ($m), AGR (%), CAGR (%), 2016-2027
Table 4.32 Drivers and Restraints for Entyvio, 2017-2027
Table 4.33 World Simponi Forecast: Revenues ($m), AGR (%), CAGR (%), 2016-2027
Table 4.34 Drivers and Restraints for Simponi, 2017-2027
Table 4.35 World Uceris Forecast: Revenues ($m), AGR (%), CAGR (%), 2016-2027
Table 4.36 Drivers and Restraints for Uceris, 2017-2027
Table 5.1 IBD Drug Revenues ($m) by Leading Country, 2016
Table 5.2 US IBD Drug Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2016-2027
Table 5.3 Japanese IBD Drug Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2016-2027
Table 5.4 EU5 IBD Drug Market Forecasts: Revenues ($m), AGR (%), CAGR (%), 2016-2021
Table 5.5 EU5 IBD Drug Market Forecasts: Revenues ($m), AGR (%), CAGR (%), 2021-2027
Table 5.6 German IBD Drug Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2016-2027
Table 5.7 French IBD Drug Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2016-2027
Table 5.8 UK IBD Drug Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2016-2027
Table 5.9 Spanish IBD Drug Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2016-2027
Table 5.10 Italian IBD Drug Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2016-2027
Table 5.11 BRIC IBD Drug Market Forecasts: Revenues ($m), AGR (%), CAGR (%), 2016-2021
Table 5.12 BRIC IBD Drug Market Forecasts: Revenues ($m), AGR (%), CAGR (%), 2021-2027
Table 5.13 Brazilian IBD Drug Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2016-2027
Table 5.14 Russian IBD Drug Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2016-2027
Table 5.15 Indian IBD Drug Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2016-2027
Table 5.16 Chinese IBD Drug Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2016-2027
Table 6.1 Key Patent dates for marketed and pipeline products
Table 6.2 Selected IL Inhibitors in Clinical Development, 2016
Table 6.3 Selected CAM Inhibitors in Clinical Development, 2016
Table 6.4 Selected TNF-α Inhibitors in Clinical Development, 2016
Table 6.5 Selected Stem Cell Therapies in Clinical Development, 2016
Table 6.6 Selected JAK Inhibitors in Clinical Development, 2016
Table 6.7 Selected Toll-like Receptor Agonist in Clinical Development, 2016
Table 6.8 Selected Other Classes in Clinical Development, 2016
Table 7.1 Strengths, Weaknesses, Opportunities and Threats in the IBD Drug Market, 2016
Table 7.2 Social, Technological, Economic and Political Forces on the IBD Drug Market, 2016
Table 8.1 Top 4 Companies for IBD Drugs: Revenues ($m) and Market Shares (%), 2016
Table 8.2 AbbVie Revenues ($m) and Market Share (%), 2016
Table 8.3 Janssen Biotech Revenues ($m) and Market Share (%), 2016
Table 8.4 Allergan Revenues ($m) and Market Share (%), 2016
Table 8.5 Shire Revenues ($m) and Market Share (%), 2016
Table 9.1 Global IBD Revenue Forecasts ($m), CAGR (%) and Market Share (%) by Product Category, 2016, 2021, 2027
Table 9.2 Global IBD Revenue Forecasts ($m), CAGR (%) and Market Shares (%) by Region, 2016, 2021, 2027
List of Figures
Figure 1.1 Inflammatory Bowel Disease Market Segmentation, 2016
Figure 3.1 World IBD Drugs Market Shares by Product Type (%), 2016
Figure 3.2 Global IBD Drug Market Forecast ($m), 2016-2027
Figure 3.3 World IBD Drugs Market Shares by Product Type (%), 2027
Figure 3.4 Global Biologics Forecast for IBD Market ($m), 2016-2027
Figure 3.5 Global Aminosalicylates Forecast for IBD Market ($m), 2016-2027
Figure 3.6 Global Antibiotics Forecast for IBD Market ($m), 2016-2027
Figure 3.7 Global Corticosteroids Forecast for IBD Market ($m), 2016-2027
Figure 3.8 Global Immunomodulators Forecast for IBD Market ($m), 2016-2027
Figure 4.1 World Humira Revenue Forecast ($m), 2016-2027
Figure 4.2 World Remicade Forecast ($m), 2016-2027
Figure 4.3 World Asacol Forecast ($m), 2016-2027
Figure 4.4 World Pentasa Forecast ($m), 2016-2027
Figure 4.5 World Lialda Forecast ($m), 2016-2027
Figure 4.6 World Tysabri Forecast ($m), 2016-2027
Figure 4.7 World Xifaxan Forecast ($m), 2016-2027
Figure 4.8 World Cimzia Forecast ($m), 2016-2027
Figure 4.9 World Entocort Forecast ($m), 2016-2027
Figure 4.10 World Neoral Forecast ($m), 2016-2027
Figure 4.11 World Medrol Forecast ($m), 2016-2027
Figure 4.12 World Canasa Forecast ($m), 2016-2027
Figure 4.13 World Apriso Forecast ($m), 2016-2027
Figure 4.14 World Azulfidine Forecast ($m), 2016-2027
Figure 4.15 World Entyvio Forecast ($m), 2016-2027
Figure 4.16 World Simponi Forecast ($m), 2016-2027
Figure 4.17 World Uceris Forecast ($m), 2016-2027
Figure 5.1 Global IBD Drug Market by Leading Country (%), 2016
Figure 5.2 Global IBD Drug Market by Leading Country (%), 2027
Figure 5.3 US IBD Drug Market Forecast ($m), 2016-2027
Figure 5.4 Japanese IBD Drug Market Forecast ($m), 2016-2027
Figure 5.5 EU5 IBD Drug Market Forecasts ($m), 2016-2027
Figure 5.6 German IBD Drug Market Forecast ($m), 2016-2027
Figure 5.7 French IBD Drug Market Forecast ($m), 2016-2027
Figure 5.8 UK IBD Drug Market Forecast ($m), 2016-2027
Figure 5.9 Spanish IBD Drug Market Forecast ($m), 2016-2027
Figure 5.10 Italian IBD Drug Market Forecast ($m), 2016-2027
Figure 5.11 BRIC IBD Drug Market Forecasts ($m), 2016-2027
Figure 5.12 Brazilian IBD Drug Market Forecast ($m), 2016-2027
Figure 5.13 Russian IBD Drug Market Forecast ($m), 2016-2027
Figure 5.14 Indian IBD Drug Market Forecast ($m), 2016-2027
Figure 5.15 Chinese IBD Drug Market Forecast ($m), 2016-2027
Figure 8.1 Top Producers of IBD Drugs: Market Shares (%), 2016
Figure 8.2 AbbVie Assets – Marketed and Pipeline 2016
Figure 8.3 AbbVie Deals and Partnerships 2011 - 2016
Figure 8.4 Janssen Assets – Marketed and Pipeline 2016
Figure 8.5 Janssen – Deals and Partnerships 2011 - 2016
Figure 8.6 Allergan Assets – Marketed and Pipeline 2016
Figure 8.7 Allergan – Deals and Partnerships 2011 - 2016
Figure 8.8 Shire Assets – Marketed and Pipeline 2016
Figure 8.9 Shire – Deals and Partnerships 2011 - 2016
Visiongain Pharma
Visiongain Pharma
Visiongain Pharma
